IL262266B2 - Compositions and methods for preparing antibodies based on the use of LOCI enhancer expression - Google Patents

Compositions and methods for preparing antibodies based on the use of LOCI enhancer expression

Info

Publication number
IL262266B2
IL262266B2 IL262266A IL26226618A IL262266B2 IL 262266 B2 IL262266 B2 IL 262266B2 IL 262266 A IL262266 A IL 262266A IL 26226618 A IL26226618 A IL 26226618A IL 262266 B2 IL262266 B2 IL 262266B2
Authority
IL
Israel
Prior art keywords
rrs
vector
nucleotide sequence
nucleic acid
sequence encoding
Prior art date
Application number
IL262266A
Other languages
English (en)
Hebrew (he)
Other versions
IL262266A (en
IL262266B1 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL262266A publication Critical patent/IL262266A/en
Publication of IL262266B1 publication Critical patent/IL262266B1/en
Publication of IL262266B2 publication Critical patent/IL262266B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL262266A 2016-04-20 2017-04-20 Compositions and methods for preparing antibodies based on the use of LOCI enhancer expression IL262266B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Publications (3)

Publication Number Publication Date
IL262266A IL262266A (en) 2018-11-29
IL262266B1 IL262266B1 (en) 2024-09-01
IL262266B2 true IL262266B2 (en) 2025-01-01

Family

ID=58701851

Family Applications (2)

Application Number Title Priority Date Filing Date
IL262266A IL262266B2 (en) 2016-04-20 2017-04-20 Compositions and methods for preparing antibodies based on the use of LOCI enhancer expression
IL314779A IL314779A (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL314779A IL314779A (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Country Status (15)

Country Link
US (2) US11512144B2 (cg-RX-API-DMAC7.html)
EP (1) EP3445781A1 (cg-RX-API-DMAC7.html)
JP (3) JP7096770B2 (cg-RX-API-DMAC7.html)
KR (1) KR102547738B1 (cg-RX-API-DMAC7.html)
CN (2) CN109195986B (cg-RX-API-DMAC7.html)
AR (1) AR109451A1 (cg-RX-API-DMAC7.html)
AU (2) AU2017253241B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018071283A2 (cg-RX-API-DMAC7.html)
CA (1) CA3015389A1 (cg-RX-API-DMAC7.html)
EA (1) EA201892010A1 (cg-RX-API-DMAC7.html)
IL (2) IL262266B2 (cg-RX-API-DMAC7.html)
MX (2) MX2018012868A (cg-RX-API-DMAC7.html)
SG (2) SG11201807885PA (cg-RX-API-DMAC7.html)
TW (2) TWI827531B (cg-RX-API-DMAC7.html)
WO (1) WO2017184832A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445781A1 (en) * 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
SG11202110076PA (en) 2019-04-02 2021-10-28 Chugai Pharmaceutical Co Ltd Method of introducing target-specific foreign gene
EP3990649A1 (en) * 2019-06-26 2022-05-04 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
KR20240099288A (ko) 2021-10-18 2024-06-28 리제너론 파마슈티칼스 인코포레이티드 아데노바이러스-연관 바이러스 폴리뉴클레오티드를 포함하는 진핵세포
US20230287460A1 (en) 2021-10-18 2023-09-14 Regeneron Pharmaceuticals, Inc. Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
TW202330926A (zh) 2021-10-18 2023-08-01 美商再生元醫藥公司 聚核苷酸之受控制轉錄
WO2023122246A1 (en) * 2021-12-22 2023-06-29 Genentech, Inc. Multi-vector recombinase mediated cassette exchange
WO2023238949A1 (ja) * 2022-06-10 2023-12-14 富士フイルム株式会社 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法
US20250122482A1 (en) 2023-09-07 2025-04-17 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2014121087A1 (en) * 2013-02-01 2014-08-07 Regeneron Pharmaceuticals, Inc. Antibodies comprising chimeric constant domains

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
DK1531666T3 (da) 2002-05-29 2014-01-13 Regeneron Pharma Inducerbart eukaryot-ekspressionssystem
WO2004046340A2 (en) 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
CN101454345B (zh) 2006-06-02 2012-08-08 瑞泽恩制药公司 人il-6受体的高亲和力抗体
US20100105042A1 (en) 2006-12-21 2010-04-29 Smithkline Beecham Corporation Novel methods
US20080216185A1 (en) 2007-01-19 2008-09-04 Invitrogen Corporation Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
WO2010151792A1 (en) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CA2774470A1 (en) 2009-09-18 2011-03-24 Selexis S.A. Products and methods for enhanced transgene expression and processing
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
EP2606064B1 (en) 2010-08-16 2015-02-25 NovImmune S.A. Methods for the generation of multispecific and multivalent antibodies
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG11201703149RA (en) 2014-10-23 2018-02-27 Regeneron Pharma Novel cho integration sites and uses thereof
EA201890785A1 (ru) 2015-09-23 2018-10-31 Ридженерон Фармасьютикалз, Инк. Оптимизированные биспецифические анти-cd3 антитела и их применение
EP3445781A1 (en) * 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2014121087A1 (en) * 2013-02-01 2014-08-07 Regeneron Pharmaceuticals, Inc. Antibodies comprising chimeric constant domains

Also Published As

Publication number Publication date
IL262266A (en) 2018-11-29
AU2017253241A1 (en) 2018-09-20
KR20180134893A (ko) 2018-12-19
JP7781128B2 (ja) 2025-12-05
JP2024023449A (ja) 2024-02-21
WO2017184832A1 (en) 2017-10-26
IL262266B1 (en) 2024-09-01
BR112018071283A2 (pt) 2019-02-12
CN109195986B (zh) 2023-01-03
US11512144B2 (en) 2022-11-29
KR102547738B1 (ko) 2023-06-26
EA201892010A1 (ru) 2019-03-29
SG11201807885PA (en) 2018-10-30
CN116515757A (zh) 2023-08-01
AR109451A1 (es) 2018-12-12
AU2017253241B2 (en) 2024-07-04
MX2025003852A (es) 2025-05-02
KR20230098361A (ko) 2023-07-03
MX2018012868A (es) 2019-03-11
AU2024220124A1 (en) 2024-10-17
US20190233544A1 (en) 2019-08-01
JP2019515666A (ja) 2019-06-13
CA3015389A1 (en) 2017-10-26
EP3445781A1 (en) 2019-02-27
SG10202010155YA (en) 2020-11-27
US20230130799A1 (en) 2023-04-27
TWI827531B (zh) 2024-01-01
TW201803986A (zh) 2018-02-01
CN109195986A (zh) 2019-01-11
JP7096770B2 (ja) 2022-07-06
TW202415767A (zh) 2024-04-16
JP2021164479A (ja) 2021-10-14
IL314779A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
US12503520B2 (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
JP7781128B2 (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
KR102906454B1 (ko) 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
JP2025188169A (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию